Boston, Massachusetts 02129

  • Attention Deficit Hyperactivity Disorder

Purpose:

This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD compared to healthy controls.


Study summary:

This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD. Deficits in these cognitive functions are core to ADHD, and cause significant impairment and morbidity. The study will also include a cohort of healthy controls for comparison.


Criteria:

Inclusion Criteria 1. Male and female subjects 18-66 years of age 2. Healthy volunteers or volunteers with a diagnosis of ADHD in adulthood, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [American Psychiatric Association, 2013] criteria, including at least 5 moderate inattentive or impulsive-hyperactive symptoms, and onset of two symptoms of inattentive or of impulsive/hyperactive traits by the age of 12. 3. Patient will be either off stimulant medications or, if undergoing treatment with stimulants, will be asked to discontinue two days prior to the experiment, under physician-guided protocol, and allowed to resume afterwards. Subjects may resume stimulant use between the two study visits so long as they discontinue use two days prior to the second study visit. If fatigue is problematic in subjects discontinuing medication, they will be allowed to continue with the study if they are able to follow the suggested taper plan (50% of the dose day one, 25% dose day 2, stop day of visit (day 3)). 4. English-speaking Exclusion Criteria 1. Current or past history of clinically unstable psychiatric conditions such as suicidal or homicidal behavior or psychotic disorders. 2. Pregnant or nursing females. 3. Inability to participate in testing procedures 4. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy. 5. Additional exclusion criteria for healthy controls: 1. Diagnosis of psychiatric of neurological disorder 2. Ongoing treatment with any psychotropic medications.


NCT ID:

NCT04175028


Primary Contact:

Principal Investigator
Joan Camprodon, MD, PhD, MPH
Massachusetts General Hospital

Joan Camprodon, MD, PhD, MPH
Phone: 61772656348
Email: jcamprodon@mgh.harvard.edu


Backup Contact:

Patricia Cirillo, MD, PhD
Phone: 6177243217


Location Contact:

Boston, Massachusetts 02129
United States

Blake Andreou, BS
Phone: 617-724-8780
Email: bandreou@mgh.harvard.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 02, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.